Clinical Features and Outcomes of Primary Colorectal Diffuse Large B‐Cell Lymphoma: A Multicenter Retrospective Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71313 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yong-Pyo Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medi…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Durg Safety in 2023.
Abstract (Originalsprache)
Background
Primary gastrointestinal (GI) diffuse large B‐cell lymphoma (DLBCL) is a rare malignancy. Given its rarity, the nature of the disease, particularly those originating in the colorectum, remains poorly defined.
Aims
This multicenter retrospective study analyzed the clinical characteristics and treatment outcomes of primary GI DLBCL, with a focus on colorectal cases. Materials & Methods A total of 104 cases of primary GI DLBCL were retrospectively collected from three institutions (2010–2024) and classified into three groups based on the lymphoma's origin.
Results
Among 104 patients, 57.7% had gastric, 18.3% small bowel, and 24.0% colorectal DLBCL. Approximately 60% presented with limited‐stage disease (Stage I–II). All patients received front‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), achieving a complete remission (CR) rate of 81.0%. The estimated 3‐year overall survival (OS) and progression‐free survival (PFS) were 91.7% and 91.9%, respectively. Outcomes varied by disease origin, with gastric DLBCL showing the most favorable prognosis and small bowel the poorest (3‐year OS 93.9% vs. 69.3%).
Discussion
In the colorectal subgroup ( n = 25), 84.0% had disease in the ascending colon, and 70.0% had limited‐stage disease. Obstructive symptoms were the most common initial presentation. The CR rate after R‐CHOP was 80.0%, with estimated 3‐year OS and PFS of 86.7% and 72.3%, respectively. While primary tumor resection improved local disease control, it did not confer an OS benefit. During follow‐up, 13.5% of patients experienced relapse, most frequently more than 12 months after achieving CR. Relapsed or refractory primary GI DLBCL demonstrated better outcomes than conventional relapsed nodal DLBCL.
Conclusion
These findings confirm the efficacy of front‐line R‐CHOP in primary GI DLBCL and suggest that primary tumor resection may be a useful component of treatment for localized primary colorectal DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
- Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Yong-Pyo Lee
Förderung
- Ministry of Food and Durg Safety in 2023
Zitieren
APA
Lee, Y. P., Lee, M. W., & Byeon, S. (2025). Clinical Features and Outcomes of Primary Colorectal Diffuse Large B‐Cell Lymphoma: A Multicenter Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.71313
Vancouver
Lee YP, Lee MW, Byeon S. Clinical Features and Outcomes of Primary Colorectal Diffuse Large B‐Cell Lymphoma: A Multicenter Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.71313
BibTeX
@article{Lee2025,
author = {Lee, Yong-Pyo and Lee, Myung-Won and Byeon, Seonggyu},
title = {Clinical Features and Outcomes of Primary Colorectal Diffuse Large B‐Cell Lymphoma: A Multicenter Retrospective Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71313}
}
EUVIMED